Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03672773 |
Recruitment Status :
Active, not recruiting
First Posted : September 14, 2018
Last Update Posted : February 8, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Recurrent Extensive Stage Small Cell Lung Carcinoma Refractory Extensive Stage Small Cell Lung Carcinoma | Drug: Talazoparib Drug: Temozolomide | Phase 2 |
PRIMARY OBJECTIVES:
I. Evaluate the efficacy of talazoparib in combination with temozolomide as measured by objective response rate (ORR).
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of talazoparib plus temozolomide as measured by progression-free survival (PFS), overall survival, duration of response, and time to response.
II. To evaluate the safety, tolerability of talazoparib plus temozolomide. III. To evaluate the pharmacokinetics of talazoparib when given in combination with temozolomide.
IV. To evaluate patient reported outcomes per the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
EXPLORATORY OBJECTIVES:
I. To identify potential biomarkers associated with response to study drug treatment.
OUTLINE:
Participants receive temozolomide orally (PO) on days 1-5 and talazoparib PO once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up at 30 days and then up to 1 year.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 28 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (TRIO-US L-07) |
Actual Study Start Date : | October 31, 2018 |
Estimated Primary Completion Date : | October 1, 2022 |
Estimated Study Completion Date : | October 1, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (temozolomide, talazoparib)
Participants receive temozolomide PO on days 1-5 and talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Drug: Talazoparib
Given PO
Other Names:
Drug: Temozolomide Given PO
Other Names:
|
- Objective response rate defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIS)T 1.1 [ Time Frame: Up to 1 year ]Will be provided along with the corresponding exact 2-sided 95% confidence interval calculated using a method based on the F distribution.
- Progression-Free Survival (PFS) assessed by RECIST 1.1 [ Time Frame: From treatment initiation to time of first documentation of objective tumor progression or death on study due to any cause, whichever occurs first, assessed up to 1 year ]Will be summarized for the safety analysis (SA) set. Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.
- PFS assessed by RECIST 1.1 [ Time Frame: From treatment initiation to time of first documentation of objective tumor progression or death on study due to any cause, whichever occurs first, assessed up to 1 year ]Will be summarized for the SA set. Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate. Median event times and 2-sided 95% confidence interval for each median will be provided.
- Overall survival [ Time Frame: From treatment initiation to death by any cause, assessed up to 1 year ]Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.
- Duration of response (CR or PR) per RECIST 1.1 [ Time Frame: From the first documentation of objective tumor response, assessed up to 1 year ]Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.
- Time to response (CR or PR) per RECIST 1.1 [ Time Frame: From treatment initiation to the first documentation of objective tumor response, assessed up to 1 year ]Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.
- Pharmacokinetics of talazoparib - steady state trough plasma concentrations [ Time Frame: Up to 1 year ]To evaluate the pharmacokinetics (steady state trough plasma concentrations) of talazoparib when given in combination with temozolomide

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Able to provide informed consent.
- Cytologically or histologically confirmed small cell lung cancer (SCLC) with extensive-stage disease.
- Relapsed (progressed within 6 months) or refractory (progressed during or within 4 weeks of completing 1st line platinum based regimen).
- Measurable disease, as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
- Archival or fresh tissue biopsy available for exploratory analyses.
- Eastern Cooperative Oncology Group (ECOG) performance status of =< 1.
- Able to swallow the study drugs, has no known intolerance to study drugs or excipients, and able to comply with study requirements.
- Female participants of childbearing potential must have a negative pregnancy test at screening and must agree to use a highly effective birth control method (defined in protocol) from the time of the first study drug treatment through 45 days after the last study drug treatment.
- Male participants must use a condom when having sex from the time of the first study drug treatment through 105 days after the last study drug treatment. Contraception should be considered for a non-pregnant female partner of childbearing potential.
- Male and female participants must agree not to donate sperm or eggs, respectively, from the first study drug treatment through 105 days and 45 days after the last study drug treatment, respectively.
- Female participants may not be breastfeeding at baseline through 45 days after the last study drug treatment.
- Absolute neutrophil count (ANC) >= 1,500/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
- Glomerular filtration rate (by Cockroft-Gault or equivalent estimation) >= 30 mL/min
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for participants with liver metastases
- Serum total bilirubin =< 1.5 X upper limit or normal (ULN) OR direct bilirubin =< ULN for participants with total bilirubin levels > 1.5 ULN
- International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless participant is receiving anticoagulant therapy, as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
- Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Exclusion Criteria:
- Has not recovered (recovery is defined as Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 grade =< 1 or return to baseline) from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.
- Best response of progressive disease per RECIST 1.1 to first-line platinum doublet chemotherapy.
-
Has received more than 1 line of cytotoxic therapy
- Prior immunotherapy and targeted therapies (including rovalpituzumab tesirine) are allowed.
- Prior treatment with a PARP inhibitor (not including iniparib) or temozolomide.
- Use of antineoplastic therapies within 14 days before study treatment initiation.
- Use of any other investigational agent within 14 days before study treatment initiation.
-
Received radiation therapy within 14 day before study treatment initiation (single fraction palliative radiotherapy is allowed without a washout).
- Prior thoracic irradiation and prophylactic cranial irradiation are allowed.
- Major surgery within 14 days before study treatment initiation.
- Diagnosis of myelodysplastic syndrome (MDS).
- Gastrointestinal disorder affecting absorption.
- Current or anticipated use of a prohibited P-gp inhibitor or P-gp inducer or BCRP inhibitors.
- History of another cancer within 2 years before study treatment initiation, with the exception of fully treated cancers unlikely to affect the assessment of the study treatment safety or efficacy including early stage breast, prostate, nonmelanomatous skin, thyroid, cervix and endometrial cancer.
- Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the investigator.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03672773
United States, California | |
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center | |
Bakersfield, California, United States, 93309 | |
St. Joseph Heritage Healthcare | |
Fullerton, California, United States, 92835 | |
UCLA / Jonsson Comprehensive Cancer Center | |
Los Angeles, California, United States, 90095 | |
United States, Florida | |
Orlando Health, Inc. d/b/a Orlando Health UF Health Center | |
Orlando, Florida, United States, 32806 | |
United States, Indiana | |
Ft. Wayne Medical Oncology and Hematology, Inc. | |
Fort Wayne, Indiana, United States, 46804 | |
United States, Kansas | |
Cancer Center of Kansas | |
Wichita, Kansas, United States, 67214 |
Principal Investigator: | Jonathan Goldman, MD | UCLA / Jonsson Comprehensive Cancer Center |
Responsible Party: | Jonsson Comprehensive Cancer Center |
ClinicalTrials.gov Identifier: | NCT03672773 |
Other Study ID Numbers: |
18-001387 NCI-2018-01409 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) TRIO-US L-07 ( Other Identifier: UCLA / Jonsson Comprehensive Cancer Center ) |
First Posted: | September 14, 2018 Key Record Dates |
Last Update Posted: | February 8, 2022 |
Last Verified: | February 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Small Cell Lung Cancer PARP Inhibitor |
Carcinoma Lung Neoplasms Small Cell Lung Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases |
Carcinoma, Bronchogenic Bronchial Neoplasms Temozolomide Talazoparib Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors |